CTI-1601
- Generic Name
- CTI-1601
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
A Broad View of the Future of Friedreich's Ataxia Therapy
Recent review highlights advancements in Friedreich’s ataxia (FRDA) therapy, including the approval of Skyclarys (omaveloxolone) and emerging gene therapies, emphasizing the need for sensitive outcome measures and personalized medicine approaches.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath